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Both are pharmacists associated with North West London. AG is currently involved in research 
work focusing on chemical identification of new psychoactive products; CH has worked 




This brief submission highlights four features of the misuse of psychoactive substances. No 
specific recommendation is made to the committee, since the purpose of the briefing is to 
inform discussion.   
  
From the many perspectives on the topic, the features have been selected because they have 
special relevance to harm reduction for established users. Each feature is described with 
supporting evidence drawn from published literature. 
  
The following points are highlighted: 
 Users of NPS are not a homogenous group 
 Patterns of use of substances can be simple or sophisticated 
 Reported administration routes include mouth, nose and injection. 
 Harm reduction strategies (such as needle exchange) have a place in reducing the 
overall damage caused by NPS misuse. 
  
1. Introduction and purpose of this submission 
  
The text below identifies some issues relevant to usage patterns of individuals using 
psychoactive substances that in turn must influence strategies for harm reduction and treatment. 
The purpose of so doing is to inform the discussions of the committee, by highlighting some 
of the less-frequently discussed issues. Conversations with colleagues and other relevant 
professionals have suggested to us that these issues need to be more widely recognised than 
they seem to be. 
  
The term new psychoactive product (NSP) is used to include products containing active 
ingredients that may be newly created molecules or be substances that have only become 
misused over recent years. 
  
2. Scope and Information sources  
  
The identified features are expanded below, drawing on information from UK sources, the 
European Monitoring Centre for Drugs and Drug Addiction and peer reviewed literature. The 
EMCDDA collates information from across Europe on usage patterns and harm associated with 
drug misuse including NPS. Trends, substances in use and usage patterns in other European 
countries can differ from those currently seen in the UK, but this collated information helps to 
provide an overview of the problem. Overall, the information available regarding NPS is 
patchy, incomplete and fragmented, and the examples cited here are merely illustrative. 
Additionally, it should be emphasised that some usage information has been drawn from user-
reports and reliability is therefore low.  
  
3. Highlighted features  
  
3.1 User characteristics 
It is useful to remember that users of NSP are as diverse as users of traditional substances of 
misuse. Reports have specifically identified user groups including students, lesbians, gay 
bisexual and transgender (LGBT), heroin users, all age ranges, clubbers, homeless population, 
prisoners, as well as users of substance misuse and the ‘needle and syringe exchange schemes’. 
The European Drug Report 20151 describes users as being “as diverse as school students, party-
goers, psychonauts, prisoners and injecting drug users”.  
  
3.2 Patterns of use 
Linked to the diversity of users, patterns of use can range from using a single product on a 
solitary or occasional basis, to sophisticated use of cocktails of products with a specific purpose 
in mind. NPS products sold may contain a single or multiple active ingredients. In 2014, the 
Home Office Forensic Early Warning System (FEWS) reported that of samples analysed that 
contained NPS, about 91% were identified as mixtures of either two or three different active 
components. The proportion of controlled drugs in the products varied with source2. Post 
mortem analysis not infrequently reveals that more than one psychoactive substance has been 
used3.   
  
Usage patterns are believed to include deliberate use of combinations of drugs with stimulant, 
hallucinogenic or sedative properties4. As early as 2011/12, the crime survey for England and 
Wales (CSEW) reported that ketamine users generally have high rates of simultaneous poly-
substance use5. 
  
Some NPS are thought to be used as cheaper or more available alternatives for traditional 
addictive drugs such as heroin for example6 but, on the basis of their known pharmacology and 
evidence of usage patterns, several NPS are themselves thought to be addictive. Examples 
include ethylphenidate7, methoxetamine8 and cathinones1.  
  
3.3 Routes and modes of administration 
As with traditional substances of misuse, many modes of administration are used. The UK 
Project NEPTUNE has reported that NPS are usually snorted, smoked, injected, ingested, 
ingested via bombing (placed in paper, made like a ball and ingested) or dissolved in alcohol9. 
The fact that several NPS are used by injection, introduces the additional problems of harm 
such as infection, necrosis, spread of disease etc. Specific examples of injected products 
include e.g. cathinones including mephedrone6, methoxetamine10 and 25I-NBOMe11.  
  
3.4 Harm reduction 
Injection of traditional substances of misuse has long been known to be associated with harm 
beyond that of the substance itself. Strategies such as needle and syringe exchange facilities 
are proven to reduce harm. The European Drug Report 20151 identifies “needle and syringe 
exchange programmes based in low-threshold services” as an important response to the 
challenges posed by NPS. 
  
Harm reduction via provision of sexual health services has also been highlighted by the 
EMCDDA1, particularly in the context of hepatitis and HIV transmission. As well as the 
established need of for infection control amongst those injecting substances, ketamine for 
example, has been linked to pronounced sexual health risks12. The provision of sexual health 




By stressing the diversity amongst users and of products used, along with the overlap with 
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